Startseite > Aktien > Psyence Biomedical > Nachrichten
    Psyence Biomedical Aktie
    Aktie
    ISIN: CA74449F1009 WKN: A3EK39 SYM: PBM Land Flagge CA Kanada
    Zur Watchlist hinzufügenZur Watchlist hinzufügen Zum Portfolio hinzufügenZum Portfolio hinzufügen
    0,1094
     
    USD
    +2,24 %
    +0,0024 USD
    Letzter Kurs 22:30:00 NYSE
    Geldkurs
    22:02:00
    0,1092
     
    USD
    300 STK
    Briefkurs
    22:02:00
    0,1093
     
    USD
    100 STK

    Psyence Biomedical Aktie kaufen

    Kauf
    Verkauf

    Neueste Nachrichten

    Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant
    04.10.24 · globenewswire · Psyence BiomedicalEnglische Nachricht
    Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs
    19.09.24 · globenewswire · Psyence BiomedicalEnglische Nachricht
    Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones
    16.09.24 · globenewswire · Psyence BiomedicalEnglische Nachricht
    Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq
    13.09.24 · globenewswire · Psyence BiomedicalEnglische Nachricht
    Psyence Biomed Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care
    09.09.24 · globenewswire · Psyence BiomedicalEnglische Nachricht
    Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant
    06.09.24 · globenewswire · Psyence BiomedicalEnglische Nachricht
    Psyence Biomed Announces Worldwide Exclusive Licensing Agreement with PsyLabs to Supply Nature-Derived Psilocybin to be Evaluated as a Potential Treatment for Alcohol Use Disorder (AUD) and Other Substance Use Disorders (SUDs)
    04.09.24 · globenewswire · Psyence BiomedicalEnglische Nachricht
    Psyence Biomed Announces Registration Statement on Form F-1 for Up to $25 Million Equity Line of Credit with White Lion Capital, LLC, Declared Effective by SEC
    30.08.24 · globenewswire · Psyence BiomedicalEnglische Nachricht
    Psyence Biomed to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024
    27.08.24 · globenewswire · Psyence BiomedicalEnglische Nachricht
    Optimi Health and Psyence Biomedical Sign Non-Binding Letter of Intent to Advance Global Psilocybin Drug Development
    13.08.24 · globenewswire · Psyence BiomedicalEnglische Nachricht
    Optimi Health and Psyence Biomedical Sign Non-Binding Letter of Intent to Advance Global Psilocybin Drug Development
    13.08.24 · newsfile · Psyence BiomedicalEnglische Nachricht
    Psyence Biomed Enters Into $25 Million Common Stock Purchase Agreement with White Lion Capital, LLC
    31.07.24 · globenewswire · Psyence BiomedicalEnglische Nachricht